Recombinant Biotinylated Mouse IgG2a Fc, Avi Tag (Avitag™), 25 µg

Background
Immunoglobulin G2 (IgG2) is a member of many immunoglobulin G developed and secreted by effective B cells. In wake of cutting by pepsin, IgG is divided into two F(ab)s with one antigen binding site and a high conserved Fc segment. The Fc segment bears a highly conserved N-glycosylation site. There are two members of IgG2: IgG2a and IgG2b. It was found that IgG2a was superior to IgG1 in activating complement. The glycosylation of the circulating immunoglobulin-? (IgG) antibody molecules changes in rheumatoid arthritis.

Source
Recombinant Biotinylated Mouse IgG2a Fc, Avitag (IGA-M8210) is expressed from human 293 cells (HEK293). It contains AA Glu 98 - Lys 330 (Accession # P01863).
Predicted N-terminus: Glu 98

Molecular Characterization
This protein carries an Avi tag at the C-terminus.
The protein has a calculated MW of 28.2 kDa. The protein migrates as 32-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per µg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "The spatial resolution limit of phagocytosis"
Eisentraut, Sabri, Kress
Biophys J (2023)mann, Järnum, Runström et al
Transplantation (2021)
(2) "Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine"
Nielsen, Barrett, Davis et al
JCI Insight (2023) 8 (2)
(3) "Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC"
Kolluri, Li, Li et al
Hepatol Commun (2023) 7 (2), e0022
Showing 1-3 of 10529 papers.